Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.9 ILa | -1.24% | -1.85% | -58.38% |
Sales 2024 * | 14.36M 5.32B | Sales 2025 * | 27.77M 10.28B | Capitalization | 52.01M 19.26B |
---|---|---|---|---|---|
Net income 2024 * | -47M -17.41B | Net income 2025 * | -36M -13.33B | EV / Sales 2024 * | 3.62 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.87 x |
P/E ratio 2024 * |
-2.17
x | P/E ratio 2025 * |
-
| Employees | 79 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.64% |
Latest transcript on BioLineRx Ltd.
1 week | -1.23% | ||
Current month | -8.52% | ||
1 month | -5.29% | ||
3 months | -48.40% | ||
6 months | -61.11% | ||
Current year | -57.85% |
Managers | Title | Age | Since |
---|---|---|---|
Philip Serlin
CEO | Chief Executive Officer | 63 | 09-05-23 |
Mali Zeevi
DFI | Director of Finance/CFO | 48 | 08-12-31 |
Irit Gliko-Kabir
CTO | Chief Tech/Sci/R&D Officer | - | 17-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sandra Panem
BRD | Director/Board Member | 77 | 14-02-23 |
Avraham Molcho
BRD | Director/Board Member | 66 | 09-12-31 |
Aharon Schwartz
CHM | Chairman | 80 | 03-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-20 | 15.9 | -1.24% | 154 201 |
24-05-19 | 16.1 | 0.00% | 705,484 |
24-05-16 | 16.1 | -1.23% | 712,443 |
24-05-15 | 16.3 | +0.62% | 388,713 |
Delayed Quote TEL AVIV STOCK EXCHANGE, May 20, 2024 at 08:57 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-57.85% | 52.01M | |
+9.70% | 115B | |
+11.69% | 106B | |
-2.65% | 21.96B | |
-14.27% | 21.87B | |
-5.29% | 19.21B | |
-4.36% | 18.08B | |
-38.29% | 17.71B | |
+7.20% | 14.32B | |
+35.82% | 12.42B |
- Stock Market
- Equities
- BLRX Stock